Trung has over 15 years of STEMM capabilities in driving fundamental discovery and clinical translation projects, along with delivering specialist research evaluation services for several large-scale strategic & funding priorities (e.g., principal investigators; medical science associations; multi-institutional national/international partnerships). With an interdisciplinary synthesis & quality outcomes focus, he is advancing: (I) Precision Pain Medicine R&D program to delineate genetically supported risk & protective factors, transdiagnostic subtypes/biotypes and novel therapeutic targets for chronic pain & its many comorbidities (e.g., dementia; Parkinson’s disease; psychiatric, sleep & cardiometabolic disorders); (II) Vestibulocortical stimulation (VCS) therapy trials in these complex conditions and its preventative health utility — i.e., improving insight & reversing maladaptive neuroplasticity/inflammation following injury/trauma (e.g., acquired brain injuries, concussion, PTSD) — with both local & U.S. clinicians across multiple medical disciplines and in other prominent pain presentations (e.g., endometriosis; functional neurological disorders; multiple sclerosis). Trung also actively supports the Australian entrepreneurship ecosystem through Health Tech Innovation QLD — and AIMOS: the Association for Interdisciplinary Meta-Research & Open Science — in its continuing commitment to improving research quality, integrity & culture for the meaningful benefit of our broader community. His PhD in Neuroscience was undertaken with Jack Pettigrew MBBS FRS, followed by an NHMRC Clinical Research Fellowship at Monash University & Alfred Health examining a bistable (quantum) switching biomarker of neurocognitive (dys)regulation and VCS in persistent pain, bipolar & depressive disorders.